• Akero Therapeutics Inc AKRO.OQ reported a quarterly adjusted loss of 99 cents​​ per share for the quarter ended December 31, identical to the same quarter last year. The mean expectation of nine analysts for the quarter was for a loss of $1.15 per share. Wall Street expected results to range from $-1.39 to $-1.07 per share.

• Reported revenue was zero​; analysts expected zero.

• Akero Therapeutics Inc's reported EPS for the quarter was a loss of 99 cents​.

• The company reported a quarterly loss of $70.03 million.

• Akero Therapeutics Inc shares had risen by 71.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Akero Therapeutics Inc is $77.50

This summary was machine generated from LSEG data February 28 at 01:11 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)